Compositions comprising thymoquinone and omega-3 fatty acids

Abstract

The present invention provides a composition comprising a synergistic combination of thymoquinone and one or more omega-3 fatty acids, wherein the molar ratio between said thymoquinone and said one or more omega-3 fatty acids is at least 1:7. The present invention also provides a method of using said composition to treat or prevent inflammatory conditions.

1 . A composition comprising a combination of TQ and one or more omega-3 fatty acids, wherein the molar ratio between said TQ and said one or more omega-3 fatty acids is at least 1:7. 
     
     
         2 . The composition of  claim 1 , wherein the omega-3 fatty acids are in the form of free fatty acids, ethyl esters, or combinations thereof. 
     
     
         3 . The composition according to  claim 1 , wherein the molar ratio between TQ and the omega-3 fatty acids is in the range of 1:7-1:200. 
     
     
         4 . The composition according to  claim 1 , wherein the molar ratio between TQ and the omega-3 fatty acids is in the range of 1:7-1:150. 
     
     
         5 . The composition according to  claim 1 , wherein the molar ratio between TQ and the omega-3 fatty acids is in the range of 1:7-1:140. 
     
     
         6 . The composition according to  claim 1 , wherein the TQ is present in the composition in a form selected from the group consisting of intact BC seeds, ground BC seeds, BC seed oil, solvent extracts of BC seeds, supercritical CO 2  extracts of BC oils, and/or partially purified extracts, purified extracts and/or fractions thereof. 
     
     
         7 . The composition according to  claim 1 , wherein the TQ is present in the composition in a form selected from the group consisting of intact oregano seeds, ground oregano seeds, oregano seed oil, solvent extracts of oregano seeds, supercritical CO 2  extracts of oregano oils, and/or partially purified extracts, purified extracts and/or fractions thereof. 
     
     
         8 . The composition according to  claim 1 , wherein the TQ is synthetic TQ. 
     
     
         9 . The composition according to  claim 1 , wherein the one or more omega-3 fatty acids are selected from the group consisting of eicosapentaenoic acid (EPA), docosahexanoic (DHA) and alpha-linoienic acid (ALA). 
     
     
         10 . The composition of  claim 1 , wherein the omega-3 fatty acids are highly concentrated oils containing a minimum of 50% w/w DHA & EPA in their free fatty acid or ethyl ester forms, and wherein the molar ratio between DHA and EPA is in the range of 1:1000 to 1000:1. 
     
     
         11 . The composition of  claim 1 , further comprising 3,3-diindolylmethane (DIM). 
     
     
         12 . A dosage form comprising the composition according to  claim 1 , wherein said dosage form is selected from the group consisting of a soft gelatin capsule, a sprinkle capsule, a sachet, a tablet, a syrup or other pharmaceutically acceptable oral dosage form. 
     
     
         13 . The dosage form according to  claim 12 , wherein the amount of TQ in said dosage form is 1-15% of the amount of omega-3 fatty acid. 
     
     
         14 . The dosage form according to  claim 12 , further comprising 3,3-diindolylmethane (DIM), wherein the amount of TQ in said dosage form is 1-15% of the amount of omega-3 fatty acid and the amount of DIM is 1-15% of the amount of omega-3 fatty acid. 
     
     
         15 . A method for the treatment, prevention, attenuation or inhibition of the progression of an inflammatory disease or a disease having an inflammatory component in a mammalian subject, comprising the administration of a composition according to  claim 1 . 
     
     
         16 . The method according to  claim 15 , wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, pelvic inflammatory disease, atherosclerosis, periodontitis, ulcerative colitis, Crohn's disease, psoriasis, multiple sclerosis, AMD, other possible eye inflammatory related diseases, inflammatory bowel disease and asthma. 
     
     
         17 . The method according to  claim 15 , wherein the mammalian subject is a human. 
     
     
         18 . A composition according to  claim 1  for use as a medicament. 
     
     
         19 . A composition according to  claim 1  for use in the treatment, prevention, attenuation or inhibition of the progression of an inflammatory disease or a disease having an inflammatory component.